Mutual of America Capital Management LLC Purchases 5,585 Shares of Omnicell, Inc. $OMCL

Mutual of America Capital Management LLC increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 4.7% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 125,286 shares of the company’s stock after buying an additional 5,585 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Omnicell were worth $3,683,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Omnicell by 37.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after buying an additional 458 shares during the period. AlphaQuest LLC boosted its holdings in shares of Omnicell by 79.0% during the 1st quarter. AlphaQuest LLC now owns 6,400 shares of the company’s stock worth $224,000 after buying an additional 2,824 shares during the period. New Age Alpha Advisors LLC acquired a new position in Omnicell during the 1st quarter valued at $233,000. EntryPoint Capital LLC raised its stake in Omnicell by 21.6% during the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company’s stock valued at $233,000 after purchasing an additional 1,184 shares during the last quarter. Finally, EP Wealth Advisors LLC acquired a new position in Omnicell during the 1st quarter valued at $245,000. 97.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on OMCL. Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Piper Sandler cut their target price on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 11th. Finally, Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, July 21st. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $46.71.

Omnicell Trading Up 1.4%

Shares of OMCL stock opened at $30.89 on Friday. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 61.78, a P/E/G ratio of 6.47 and a beta of 0.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. The firm has a fifty day moving average of $31.45 and a 200-day moving average of $30.21.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company had revenue of $290.56 million during the quarter, compared to analysts’ expectations of $275.57 million. During the same quarter in the prior year, the company posted $0.51 EPS. The business’s revenue was up 5.0% on a year-over-year basis. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the sale, the executive vice president owned 110,653 shares in the company, valued at $3,679,212.25. This trade represents a 3.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.52% of the stock is owned by company insiders.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.